Hertfordshire

IGEL Expands Global Sales Leadership; Adds New Sales Executives for DACH, UK/Ireland and International Markets

Retrieved on: 
Tuesday, September 19, 2023
Software as a service, University, Hertfordshire, University of Hertfordshire, Standard German phonology, CX, Fields, Software, Red, EMC, BMC Software, Acronis, Emerging market, Data as a service, Cornell University, Red Hat, ANZ, Middlesex University, Vodafone, Growth, IGEL, Video game, Management, Citrix Systems, International, Thunderhead, DACH

SAN FRANCISCO and BREMEN, Germany, Sept. 19, 2023 /PRNewswire/ -- IGEL, provider of the managed endpoint operating system for secured access to any digital workspace, today announced the global expansion of its sales leadership with new executives for the DACH region (including Germany, Austria and Switzerland) as well as UK/Ireland, Australia/New Zealand (ANZ) and additional international markets. Former Red Hat global executive, Brian Cornell has been named Vice President, Sales for the DACH region. Former Citrix sales leader Darren Fields has been named Vice President, Sales for UK/Ireland and International markets.

Key Points: 
  • Former Red Hat global executive, Brian Cornell has been named Vice President, Sales for the DACH region.
  • Former Citrix sales leader Darren Fields has been named Vice President, Sales for UK/Ireland and International markets.
  • "IGEL is strategically positioned to lead the industry, worldwide, with the secure endpoint operating system for the enterprise," said Klaus Oestermann, CEO, IGEL.
  • Also joining the IGEL team is Justin Thorogood who is named Director of Channels, UK, Ireland and Emerging Markets.

SpectrumX Adds Financial Controller to Management Team

Retrieved on: 
Tuesday, December 6, 2022
Medical Devices, Medical Supplies, Infectious Diseases, Finance, Professional Services, Biotechnology, Health, Pharmaceutical, Other Professional Services, IPO, NHS, London, Virus, Infection, Hypochlorous acid, Hertfordshire, Bacteria, CFO, Fungus, London Stock Exchange, Accounting, Risk management, ACA, University of Hertfordshire, Johnson Matthey, Human, Health, Interest, University, PricewaterhouseCoopers, Pharmaceutical industry, Security (finance)

SpectrumX, a UK-based healthcare and pharmaceutical company, today announces the appointment of Scott Grant as financial controller.

Key Points: 
  • SpectrumX, a UK-based healthcare and pharmaceutical company, today announces the appointment of Scott Grant as financial controller.
  • Grant will manage financial reporting and control activities for SpectrumX.
  • Most recently, he worked as lead finance business partner, and previously as financial controller, at Johnson Matthey, where he worked across the life science and technology business.
  • Damien Hancox, CEO of SpectrumX, said: We are delighted to have Scott join our team.

Evox Therapeutics Appoints Peter Jones as Vice President of CMC

Retrieved on: 
Thursday, April 14, 2022
Aston, Process, Engineering, Hertfordshire, Chemical engineering, GlaxoSmithKline, Orchard, Biology, Royal Academy of Arts, Royal Academy of Engineering, Oxford BioMedica, Master of Science, API, Central nervous system, Brain, GLOBE, Biochemical engineering, Patient, Cell, Tissue, Institution of Chemical Engineers, Technology, Lego Star Wars: The Complete Saga, CAR, CD19, University of Hertfordshire, CMC, University college, Bachelor of Science, Exosome, Oxford, Antibody, University, Aston University, Health, Seminal vesicles, Therapy, Pharmaceutical industry, Fine chemical, Genzyme, Discovery

OXFORD, United Kingdom, April 14, 2022 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (Evox or the Company), a leading exosome therapeutics company, announces the appointment of Peter Jones as Vice President of CMC.

Key Points: 
  • OXFORD, United Kingdom, April 14, 2022 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (Evox or the Company), a leading exosome therapeutics company, announces the appointment of Peter Jones as Vice President of CMC.
  • Mr. Jones has more than 30 years of process development experience in the biopharmaceutical industry, building and leading cross-functional teams to support clinical and commercial development.
  • Before joining Evox, he was Executive Director, Process Development at Autolus Therapeutics plc, where he led late-stage CMC activities for the AUTO1 (obe-cel) CD19 CAR T cell therapy program.
  • Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of therapeutics.

Blackstone and Hudson Pacific Properties Announce Plans for New World-Class Film and TV Studios in the UK

Retrieved on: 
Monday, August 2, 2021
Commercial Building & Real Estate, Construction & Property, Finance, Entertainment, Banking, REIT, Professional services, Mobile Entertainment, TV and Radio, Film & Motion Pictures, Hudson Pacific Properties, Hudson, BX, Blackstones, Blackstone, Hertfordshire, Blackstone, Hudson Pacific Properties, BLACKSTONE, HUDSON PACIFIC PROPERTIES

Blackstone (NYSE: BX) and Hudson Pacific Properties (NYSE: HPP) plan to create a major new centre for film, TV and digital production in Broxbourne, Hertfordshire.

Key Points: 
  • Blackstone (NYSE: BX) and Hudson Pacific Properties (NYSE: HPP) plan to create a major new centre for film, TV and digital production in Broxbourne, Hertfordshire.
  • This transaction is a continuation of Blackstones existing joint venture with Hudson Pacific, a leading Los Angeles-based office and studio owner and operator.
  • Victor Coleman, Chairman and CEO of Hudson Pacific, said: We are thrilled to expand our Sunset Studios platform in the UK, a global hub for film and television production.
  • We look forward to working with Blackstone and Hudson Pacific to help deliver significant positive change in Broxbourne.

Stake.com and Watford FC Announce New Multi-Year Principal Partnership

Retrieved on: 
Thursday, July 22, 2021
Watford F.C., Association football clubs, Watford, Sports betting, Local government in England, Hertfordshire

WATFORD, England, July 22, 2021 /PRNewswire/ -- Watford today announced a new multi-year partnership with Stake.com, the leading crypto casino and sports betting platform worldwide. Starting in 2021/22, the club-record deal will see Stake become the club's principal shirt sponsor as they return to the Premier League.

Key Points: 
  • Watford today announced a new multi-year partnership with Stake.com, the leading crypto casino and sports betting platform worldwide.
  • WATFORD, England, July 22, 2021 /PRNewswire/ --Watford today announced a new multi-year partnership with Stake.com , the leading crypto casino and sports betting platform worldwide.
  • Starting in 2021/22, the club-record deal will see Stake become the club's principal shirt sponsor as they return to the Premier League.
  • Scott Duxbury, Watford FC Chairman, said: "We are thrilled to welcome Stake as our principal shirt sponsor ahead of the 2021/2022 season.

Watford Announces Purchase of Axeria IARD

Retrieved on: 
Friday, April 9, 2021
Other Professional Services, Professional services, Insurance, Finance, Watford, Insurance, Forward-looking statement, Geography of England, Hertfordshire

Watford Holdings Ltd. ("Watford") (NASDAQ: WTRE) has completed the purchase of Axeria IARD (Axeria), a property and casualty insurance company based in France.

Key Points: 
  • Watford Holdings Ltd. ("Watford") (NASDAQ: WTRE) has completed the purchase of Axeria IARD (Axeria), a property and casualty insurance company based in France.
  • Watford has acquired 100% of the capital stock of Axeria IARD from the APRIL Group.
  • Watford Chief Executive Officer Jon Levy commented: We are pleased to add Axeria to our insurance business in Europe and look forward to working with them to carry out our development in the region.
  • Watford disclaims any obligation to update these forward-looking statements because of new information, future events or circumstances or other factors.

Achilles Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2021

Retrieved on: 
Wednesday, March 10, 2021
Cancer, Melanoma, American Association for Cancer Research, Medicine, Causes of death, Health, Tyrosine kinase receptors

London, UK 10 March 2021 Achilles Therapeutics plc (Achilles or the Company), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that an abstract was selected for poster presentation at theAmerican Association for Cancer Research (AACR) Annual Meeting 2021, which will be held in a virtual format from April 10-15, 2021.

Key Points: 
  • London, UK 10 March 2021 Achilles Therapeutics plc (Achilles or the Company), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that an abstract was selected for poster presentation at theAmerican Association for Cancer Research (AACR) Annual Meeting 2021, which will be held in a virtual format from April 10-15, 2021.
  • Details of the abstract and poster presentation are as follows:
    The abstract and full session details can be found atwww.aacr.org.
  • Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell.
  • The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma.

Achilles Therapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering in the United States

Retrieved on: 
Monday, March 1, 2021
Financial markets, Stock market, Initial public offering, ADSS, Security, Red herring prospectus, SEC filing

All ADSs to be sold in the proposed IPO will be offered by Achilles.

Key Points: 
  • All ADSs to be sold in the proposed IPO will be offered by Achilles.
  • The number of ADSs to be sold and the pricing terms for the proposed IPO have not yet been determined.
  • The Registration Statement relating to the securities has been filed with the SEC but has not yet become effective.
  • These securities may not be sold, nor may offers be accepted, prior to the registration statement becoming effective.

Achilles Therapeutics Announces Independent Data and Safety Monitoring Committee Review with a Positive Recommendation to Continue with Current Study Design of the Phase I/IIa CHIRON and THETIS Trials

Retrieved on: 
Friday, February 5, 2021

Additionally, initial data from the first six patients provide encouraging evidence of cNeT engraftment.

Key Points: 
  • Additionally, initial data from the first six patients provide encouraging evidence of cNeT engraftment.
  • Based on these observations, the Company plans to increase the administered cNeT doses in the next series of monotherapy patients.
  • One patient had a reduction in the size of two of their four tumor lesions by approximately 55% and 90%.
  • Engraftment data for our cNeTs are currently available from four patients, with evidence of engraftment in two.

Achilles Therapeutics Announces Additional Financing Plans

Retrieved on: 
Friday, February 5, 2021
LGBT themes in Greek mythology, Achaean Leaders, Greek mythology, Communication, Forward-looking statement, Achilles, Option, Initial public offering, Articles

London, UK 5 February 2021 Achilles Therapeutics (Achilles or the Company), today announced that it expects to consider additional capital raising options this year, which could include an initial public offering in the United States.

Key Points: 
  • London, UK 5 February 2021 Achilles Therapeutics (Achilles or the Company), today announced that it expects to consider additional capital raising options this year, which could include an initial public offering in the United States.
  • The timing and the terms of any such offering have not yet been determined and are subject to market conditions and other factors.
  • There is no assurance that any such additional capital raising will be completed.
  • The forward-looking statements in this press release represent our views as of the date of this press release.